Watson Pharmaceuticals-Diabetic Macular Edema-Ampio Pharmaceuticals-Iridex Corporation

IRIDEX Introduces Non-Invasive MicroPulse™ Therapy for Glaucoma

MOUNTAIN VIEW, Calif., April 27, 2012 /PRNewswire/ -- IRIDEX Corporation today announced the launch of a new non-invasive, in-office glaucoma procedure based on its proprietary MicroPulse™ technology.  The new glaucoma therapy, a tissue-sparing, repeatable therapy called... read more..

source:http://www.pharmainfo.net

Ampio Awarded US and Canadian Patents that will Bolster the Commercialization of Optina™ for the treatment of Diabetic Macular Edema (DME)

GREENWOOD VILLAGE, Colo., April 27, 2012 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (Nasdaq: AMPE), a biopharmaceutical company conducting clinical trials on its three lead drugs (Ampion™, Optina™ and Zertane™), licensing distribution of these drugs and developing... read more..

source:http://www.pharmainfo.net

Equinix, Watson Pharmaceuticals Among Stocks Hitting 52-Week Highs Thursday

Equinix, Watson Pharmaceuticals Among Stocks Hitting 52-Week Highs Thursday
Fox Business - 18 hours ago
While trading on above-average volume, Equinix (EQIX) climbed today, reaching and then surpassing its previous 52-week high of $161.56. read more..

source:http://www.pharmainfo.net